Taking part in a clinical trial asks a lot from people. Participants give their time, share personal health information, and follow study protocols for months at a stretch. In return, they deserve to feel informed, respected, and cared for.
Clinical trial communications are how site staff build trust. The way research teams talk with people goes a long way to determine whether they enroll, stay through the final visit, and return for future studies.
At Remington-Davis (RDI), communication guides how we care for participants from the first conversation on. It looks a little different at each stage of a trial. Here's what it can include, and how our team puts it into practice.
Many people have never taken part in a clinical trial. They may wonder what happens at a study visit, how long a trial lasts, or what they'll be asked to do. Those open questions can make the first step hard to take.
Communication starts here in the outreach phase before anyone signs a consent form. Sites can help people feel at ease about participating in medical research by walking through steps in plain language, setting the jargon aside, and inviting questions.
That's how our team approaches every first conversation. We explain what a study involves in everyday words. We encourage people to share what's on their minds, and we take the time to answer.
When our team spends time in the community, we meet many people who have never taken part in a study. They come with thoughtful questions. What does a typical visit look like? Will this fit into my schedule? Who will I see each time? How do you know the medication is safe?
That last question comes up often. People want to understand how a medication can be safe if researchers are still studying it. It's a fair question, and it deserves a clear answer.
Dr. Roy St. John, a principal investigator at RDI, talked through this in a recent interview on community engagement and clinical trials. He starts with how clinical research works. By the time a medication reaches Phase 3, it has gone through earlier rounds of testing. The larger study helps sponsors learn how it performs across a broader group of people. Throughout the study, our team keeps a close watch on each participant's safety.
When someone reaches out about a study, they've taken a meaningful step. A timely response shows them their interest matters.
Our team follows up within 24 hours of someone expressing interest. That first conversation covers:
We answer their questions along the way, so no one moves forward feeling unsure.
The days before a first visit set the tone for the whole study. A call ahead of time helps participants know what will happen, what to bring, and how long they'll be on site. People who know what to expect tend to arrive calmer and more confident.
Our team connects with each participant before their first visit to walk them through the day. We give them space to ask questions, so they arrive feeling prepared.
People are more likely to follow instructions when they understand the purpose. Rushed conversations can lead to confusion, missed doses, or missed visits. Clear instructions also help sites stay on protocol and meet regulatory requirements.
Our coordinators and staff take their time. They review instructions, explain each procedure, and walk participants through their lab results. We want every participant to understand what to do and why it matters.
Reminders and updates help participants stay on track between visits. Participants also need a simple way to reach the study team and a timely reply when questions come up. Staying on schedule supports accurate data collection, since each completed visit and assessment adds to what the study can learn.
We send regular updates and reminders, and we're available when questions or concerns arise. That ongoing dialogue helps participants feel informed and supported.
Our structure helps, too. As an independent site, we give participants familiar faces from visit to visit. That familiarity makes honest conversations easier.
Clinical trials can give people access to new treatments. They can also give people a chance to learn more about their own health. Patient education supports both.
There's a lot to take in at enrollment, so education works best when it continues throughout the course of a study. We revisit key information at later visits, share materials in different formats, and check in to make sure participants feel confident in what they've learned.
Over time, many participants gain a clearer picture of how to manage their health. One participant might notice that taking a medication at a different time of day improves their energy. Another might start to see how their diet affects their blood sugar. Those insights stay with them after the study ends.
Every study has an end date. Many last six months or a year. The relationship between a site and its participants can continue well beyond that.
Staying in touch serves participants first. When a trial closes, they may lose access to a medication that seemed to help them. A site that keeps in contact can let them know when a new study fits their needs.
Our team builds long-term relationships with the people who take part in our studies. We stay in touch over time, and when a new study fits someone's needs, we reach out. Many past participants are glad to get involved again. In the interview, Dr. St. John describes the goal as treating participants like family.
Sylvester Thompson experienced this firsthand. He has taken part in several of our studies. With his family living in the South, he has come to think of RDI as a second home.
Clinical trial communication runs from the first outreach to the last follow-up call. Each stage asks for something a little different: comfort before enrollment, clarity during the study, and connection after it ends. Through all of it, participants should feel heard and valued.
That's what we work toward with every person we meet, from the first conversation to the final visit and beyond.
Learn more about how our team can support your next trial with a patient-centered experience.
Contemporary clinical trial communication meets participants where they are. Some people prefer a phone call. Others want a quick text or an email they can read on their own time. Sites should ask each participant how they'd like to be reached at the start of a study and note it in their records.
The channel can also match the message. A text works well for a visit reminder. A phone call or face-to-face conversation fits better for lab results or a change to the study schedule. Our team asks participants how they prefer to hear from us and follows their lead.
Breaks tend to happen at handoffs and during quiet stretches. Common weak points include:
Sites can close these gaps by planning communication for each one: fast follow-up, pre-visit check-ins, regular reminders, a consistent point of contact, and a plan to stay in touch after the study.
Effective clinical trial communication is clear, timely, and personal. Best practices include:
Clear, consistent communication removes many of the reasons people leave a study. Participants who understand their schedule and instructions run into fewer surprises. Regular contact keeps the study top of mind. A strong relationship with the site team gives people a reason to keep coming back through the final visit.
Often enough to keep participants informed without overwhelming them. A good rhythm includes contact before each visit, a check-in after any significant result or change, and an open line for questions in between. Ask participants what works for them and adjust.
Sponsors should ask how a site handles first contact, pre-visit preparation, reminders, and follow-up. Look for a defined follow-up timeline, a named point of contact for participants, and a plan for patient education. Independent sites can often offer participants more continuity from visit to visit.
When a trial ends, participants typically stop receiving the study medication and return to their regular care. A site that stays in touch can let them know when a new study fits their needs. We value keeping those relationships going long after the final visit.